Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Unknown 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Leukemia, Prolymphocytic, B-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Myeloid, Acute 2Study of Risk Factors for IPMNs Degeneration at the Nancy CHRU 1Stomach Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myeloid 1Leukemia, Large Granular Lymphocytic 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Rituximab 57Cyclophosphamide 40Vincristine 26Prednisone 25Doxorubicin 22Cytarabine 18Lenalidomide 17Etoposide 17Gemcitabine 12Melphalan 8Filgrastim 8Cisplatin 8zanubrutinib 7Peripheral Blood Stem Cell Transplantation 7Oxaliplatin 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 7Methotrexate 7Ifosfamide 7Carmustine 7R-CHOP protocol 6fludarabine phosphate 5Vindesine 5Radiotherapy 5Dexamethasone 5Decitabine 5Busulfan 5ibrutinib 4Methylprednisolone 4Epirubicin 4Cyclosporine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Large B-Cell, Diffuse × Sensitivity and Specificity × Clear all
NCT02892695 2016-12-06

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 1/2 Unknown
10 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

NCT02819583 2016-10-25

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 1/2 Unknown
10 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

NCT02851589 2016-08-01

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 1/2 Unknown
10 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡